JFG
XFOR icon

Jefferies Financial Group’s X4 Pharmaceuticals XFOR Stock Holding History

Jefferies Financial Group’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,474
Closed -$80.4K – 2093
2026
Q1 		$80.4K Sell
19,474
-6,644
-25% -$24.9K ﹤0.01% 1620
2025
Q4 		$104K Buy
+26,118
New +$94.9K ﹤0.01% 1698

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jefferies Financial Group's XFOR Position: Q2 2026 in Review

Jefferies Financial Group sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 19,474 shares — an estimated $80.4K sold.

Jefferies Financial Group first reported a position in XFOR in Q4 2025 and held it in 2 quarters. The position peaked at $104K in Q4 2025. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Jefferies Financial Group reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 19,474 X4 Pharmaceuticals shares in Q2 2026, an estimated $80.4K.
  • Jefferies Financial Group first reported a position in X4 Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Jefferies Financial Group's X4 Pharmaceuticals position peaked at $104K in Q4 2025.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.